AU6189999A - Specific therapeutic interventions obtained by interference with redistribution and/or targetting - Google Patents
Specific therapeutic interventions obtained by interference with redistribution and/or targettingInfo
- Publication number
- AU6189999A AU6189999A AU61899/99A AU6189999A AU6189999A AU 6189999 A AU6189999 A AU 6189999A AU 61899/99 A AU61899/99 A AU 61899/99A AU 6189999 A AU6189999 A AU 6189999A AU 6189999 A AU6189999 A AU 6189999A
- Authority
- AU
- Australia
- Prior art keywords
- targetting
- redistribution
- interference
- specific therapeutic
- therapeutic interventions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA | 1998-05-29 | ||
| DKPA199801322 | 1998-10-15 | ||
| DKPA199801321 | 1998-10-15 | ||
| DKPA199801323 | 1998-10-15 | ||
| PCT/DK1999/000567 WO2000023091A2 (en) | 1998-10-15 | 1999-10-15 | Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU6189999A true AU6189999A (en) | 2000-05-08 |
Family
ID=27221225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU61899/99A Abandoned AU6189999A (en) | 1998-10-15 | 1999-10-15 | Specific therapeutic interventions obtained by interference with redistribution and/or targetting |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1146888A2 (en) |
| JP (1) | JP2003526608A (en) |
| AU (1) | AU6189999A (en) |
| CA (1) | CA2346937A1 (en) |
| WO (1) | WO2000023091A2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19950647A1 (en) * | 1999-10-21 | 2001-04-26 | Merck Patent Gmbh | Benzopyranoimidazolone and benzothiopyranoimidazolone derivatives as phosphodiesterase-VII inhibitors useful for treatment of e.g. asthma, psoriasis, osteoporosis, cachexia, sepsis, tumors and AIDS |
| US20030054531A1 (en) * | 2001-03-19 | 2003-03-20 | Decode Genetics Ehf, | Human stroke gene |
| WO2003037432A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| EP1552012A4 (en) * | 2002-09-25 | 2006-06-07 | Decode Genetics Ehf | Susceptibility gene for human stroke; methods of treatment |
| WO2004082667A1 (en) * | 2003-03-17 | 2004-09-30 | Pfizer Products Inc. | Treatment of type 1 diabetes with pde5 inhibitors |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| SG11201406552UA (en) | 2012-04-25 | 2014-11-27 | Takeda Pharmaceutical | Nitrogenated heterocyclic compound |
| US9527841B2 (en) | 2012-07-13 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors |
| JP6280912B2 (en) | 2013-03-14 | 2018-02-14 | 武田薬品工業株式会社 | Heterocyclic compounds |
| WO2015002231A1 (en) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | Heterocyclic compound |
| EP3018123B1 (en) | 2013-07-03 | 2023-05-10 | Takeda Pharmaceutical Company Limited | Amide compound |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| SG11201912010XA (en) * | 2017-06-12 | 2020-01-30 | Obsidian Therapeutics Inc | Pde5 compositions and methods for immunotherapy |
| WO2018237323A1 (en) * | 2017-06-23 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | DOMAINS OF DETABILIZATION OF PDE5A |
| EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8916806D0 (en) * | 1989-07-22 | 1989-09-06 | Univ Wales Medicine | Modified proteins |
| WO1998008955A1 (en) * | 1996-08-26 | 1998-03-05 | Signal Pharmaceuticals, Inc. | Stimulus-inducible i (kappa)b kinase [ikk] signalsome |
| EP0981642A4 (en) * | 1997-02-25 | 2003-03-19 | Univ California | NF-KAPPA B KAPPA B INHIBITOR KINASE, KAPPA B KINASE SUBUNITS AND METHODS OF USE |
| DE69824763T2 (en) * | 1997-04-07 | 2005-07-07 | Bioimage A/S | Method for screening substances having an effect on intracellular translocation |
| US5851812A (en) * | 1997-07-01 | 1998-12-22 | Tularik Inc. | IKK-β proteins, nucleic acids and methods |
-
1999
- 1999-10-15 WO PCT/DK1999/000567 patent/WO2000023091A2/en not_active Ceased
- 1999-10-15 JP JP2000576864A patent/JP2003526608A/en active Pending
- 1999-10-15 CA CA002346937A patent/CA2346937A1/en not_active Abandoned
- 1999-10-15 AU AU61899/99A patent/AU6189999A/en not_active Abandoned
- 1999-10-15 EP EP99948735A patent/EP1146888A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2346937A1 (en) | 2000-04-27 |
| EP1146888A2 (en) | 2001-10-24 |
| WO2000023091A2 (en) | 2000-04-27 |
| WO2000023091A3 (en) | 2000-07-13 |
| JP2003526608A (en) | 2003-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AUPO203996A0 (en) | Therapeutic uses | |
| AU3891299A (en) | Combination therapy for treatment of depression | |
| AU6189999A (en) | Specific therapeutic interventions obtained by interference with redistribution and/or targetting | |
| AU2463099A (en) | Gabapentin and its derivatives for the treatment of muscular and skeletal pain | |
| AU715620C (en) | Therapeutic methods and uses | |
| AU6246199A (en) | Human interleukin-b50, therapeutic uses | |
| AU1082299A (en) | Manure treatment system | |
| AU1184399A (en) | Therapeutic molecules | |
| AU2529799A (en) | Benzofuran-4-carboxamides and their therapeutic use | |
| AU4443599A (en) | Therapeutic bed | |
| AU4629399A (en) | Substituted piperazones and their therapeutic uses | |
| AU1940800A (en) | Combination therapy for the treatment of sepsis | |
| AU2566201A (en) | Compounds and methods for the treatment of pain | |
| AUPP263498A0 (en) | Novel therapeutic molecules and uses therefor | |
| AU2420201A (en) | Compounds and methods for the treatment of pain | |
| AU3300397A (en) | Cyclin-c variants, and diagnostic and therapeutic uses thereof | |
| AU4916699A (en) | 4-phenyl- and 4,5-diphenylimidazole derivatives, preparation and therapeutic application | |
| AU5005099A (en) | Benzoquinolizidine and benzoindolizidine derivatives and therapeutic uses thereof | |
| AU5524399A (en) | Inorgasmia treatment | |
| AU6404698A (en) | Treatment methods for obtaining therapeutic products and resulting products | |
| HK1038003A (en) | Therapeutic product and its use | |
| EP1150967A4 (en) | Therapeutic compounds and methods | |
| AUPP973199A0 (en) | Therapeutic compounds and methods | |
| AUPQ164599A0 (en) | Therapeutic compounds and methods | |
| AUPQ037399A0 (en) | Novel compounds and therapeutic methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |